Aquestive Therapeutics (AQST) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AQST Aquestive Therapeutics

Watchlist

2.420
-0.030-1.22%

Close Jul 2 16:00 ET

2.450
+0.030+1.24%

Post 18:55 ET

220.31MMarket Cap-5902P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | JMP Securities Reiterates Market Outperform on Aquestive Therapeutics, Maintains $9 Price Target
BenzingaJun 26 12:03 ET
JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
JMP Securities analyst Jason Butler maintains $Aquestive Therapeutics(AQST.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 38
Moomoo NewsJun 25 16:32 ET · Ratings
Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
On Tuesday, Aquestive Therapeutics Inc (NASDAQ:AQST) released topline pharmacokinetic (PK) data from the temperature / pH study of its product candidate Anaphylm (epinephrine) Sublingual Film.Anaphylm
BenzingaJun 25 13:00 ET
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Cuts Target Price to $7
Lake Street analyst Thomas Flaten maintains $Aquestive Therapeutics(AQST.US)$ with a buy rating, and adjusts the target price from $8 to $7.According to TipRanks data, the analyst has a success rate o
Moomoo NewsJun 25 09:33 ET · Ratings
Aquestive Gains After Initial Data for Allergy Candidate
Seeking AlphaJun 25 09:29 ET
Express News | Aquestive Therapeutics: Sees Filing Nda Shortly After Completion of Pediatric Study of Anaphylm
ReutersJun 25 08:04 ET

Comments

Jaguar8

May 7 15:23

$Aquestive Therapeutics(AQST.US)$
NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negati...

Meltyy

May 7 03:49

🔔 FDA PDUFA Update…

See summary 👇
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US)$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US)$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US)$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US)$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...